VIDEO: Cannabidiol and Our Progress Towards a Treatment for Refractory Epilepsy

Elizabeth Thiele, MD
Elizabeth Thiele, MD
Dr Elizabeth Thiele discusses the latest on cannabidiol research for the treatment of refractory epilepsy.

Elizabeth Thiele, MD, PhD, Director of the Pediatric Epilepsy Center at Massachusetts General Hospital, Director of the Carol and James Herscot Center for Tuberous Sclerosis Complex, and Professor of neurology at Harvard Medical School, sat down with Neurology Advisor at the 2016 Child Neurology Society Annual Meeting to discuss the state of cannabidiol research for the treatment of refractory epilepy.

Dr Thiele, who has co-authored several studies on the use of cannabidiol in children with Dravet syndrome, Lennox-Gastaut syndome, and now tuberous sclerosis complex, is hopeful that the medical community and caregivers will soon have full access to this treatment that has resulted in significant reductions in seizures and in some cases, complete seizure freedom for patients with some of the most severe types of epilepsy. 

Watch the video below to learn more about where research on cannabidiol currently stands, and how the research community is working tirelessly to get this treatment to market.